The potential defect could make the device difficult to activate in an emergency (failure to activate or increased force needed to activate) and have significant health consequences for a patient experiencing a life-threatening allergic reaction (anaphylaxis). HERTFORDSHIRE, England and PITTSBURGH, Dec. 4, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. None of the recalled lots include the authorized generic for EpiPen Auto-Injector, which is also manufactured by Meridian Medical Technologies. is 8082708 and it has a September 2020 expiration date.According to the recall notice, Mylan has notified its distributors and customers about the recall by letter and is arranging for return of all recalled products. Mylan is committed to replacing recalled devices at no cost and Mylan would like to reassure patients that there will be no additional replacement-related financial burden to them as a result of this recall. Delays in epinephrine administration have been associated with negative health consequences. The affected drug's lot No. More information about the risks and benefits of EpiPen® Auto-Injector can be found at Mylan N.V. (NASDAQ, TASE: MYL) today announced that Meridian Medical Technologies, a Pfizer company and Mylan's manufacturing partner for EpiPen® Auto-Injector, has expanded a voluntary recall … Retailers are being asked to contact consumers to explain the return process.To return the Alprazolam, consumers should call Stericycle at 888-843-0255. If you have any additional questions regarding this recall, please contact Mylan Customer Relations at 800-796-9526 or Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.This voluntary recall is being conducted with the knowledge of FDA.Epinephrine is the first-line treatment for a life-threatening allergic reaction (anaphylaxis) and access to this product is critical in the event of an emergency. Mylan NV said on Tuesday it is expanding a nationwide voluntary recall of its blood pressure medicine valsartan to include all lots, two weeks after it recalled select batches. However, the recall is being expanded to include additional lots as a precautionary measure out of an abundance of caution.The recalled product was manufactured by Meridian Medical Technologies, a Pfizer company, and distributed by Mylan Specialty between December 2015 and July 2016. The authorized generic has the exact same drug formulation, has the exact same operating instructions and is therapeutically equivalent to EpiPen Auto Injector, and may be substituted for EpiPen Auto Injector.It is important that patients continue to carry their current EpiPen Auto-Injector until they receive a replacement device. Recalls, Market Withdrawals, & Safety Alerts Mylan Pharmaceuticals is voluntarily recalling one lot of the anti-anxiety prescription drug Alprazolam nationwide because of “the potential presence of a foreign substance,” according to a recall notice posted on "Clinical impact from the foreign material, if present, is expected to be rare, but the remote risk of infection to a patient cannot be ruled out," the notice states. EpiPen (epinephrine injection, USP) and EpiPen Jr® (epinephrine injection, USP) Auto-InjectorsAn official website of the United States government: BACKGROUND: The expanded voluntary recall is being initiated in the U.S. and also will extend to additional markets in Europe, Asia, North and South America. The expanded voluntary recall is being initiated in the U.S. and also will extend to additional markets in Europe, Asia, North and South America.The recall impacts the 0.3 mg and 0.15 mg strengths of EpiPen Auto-Injector. The expanded recall of 104 lots is in addition to the 15 lots Mylan already issued a recall of two weeks ago; By Mary Kekatos Health Reporter For The incidence of the defect is extremely rare and testing and analysis across the potentially impacted lots has not identified any units with a defect. is 8082708 and it has a September 2020 expiration date. Both reports are related to the single lot that was previously recalled. Consumers with questions should call Mylan at 800-796-9526, Monday through Friday, 8 a.m. to 5 p.m. Eastern time, or email at The medicine is for the management of anxiety disorder, the short-term relief of symptoms of anxiety, and the treatment of panic disorder, with or without agoraphobia, according to Mylan.© 2020 USA TODAY, a division of Gannett Satellite Information Network, LLC. The recall is for Alprazolam 0.5 mg tablets that were distributed in July and August 2019 in 500-count bottles.